Google delists sites selling private trans hormones following UK government request
Sign up for more LGBTQ+ news and updates at TrueQueer.
Search engine giant Google has recently made headlines for reportedly delisting two pharmaceutical websites that sell hormones after a request from the UK regulatory body, the Medicines and Healthcare products Regulatory Agency (MHRA). The delisting of these sites has sparked controversy and raised concerns about access to healthcare for the transgender community in the UK.
The two pharmaceutical websites in question were reportedly blacklisted by Google at the request of the MHRA, making them inaccessible through the search engine. These websites are said to be used as an alternative way for individuals to purchase hormones, particularly for transgender individuals who may face long waiting times for NHS care or high costs associated with private healthcare practices.
An operator of one of the delisted sites, who chose to remain anonymous, expressed shock at the delisting and criticized Google for aligning with the government’s decision to restrict access to healthcare. The operator stated that while trans individuals may be left without healthcare in the short term, they are resilient and will find alternative means to access the necessary hormones.
According to reports from tech publication 404 Media, the MHRA sent two letters to Google requesting the delisting of the websites under the 2012 Human Medicines Regulations. The letters highlighted concerns about the sale and supply of unauthorized medicines to individuals in the UK, emphasizing the potential harm to public health posed by these websites.
In response to inquiries about the delisting, Google stated that it abides by local laws and regulations when determining search engine criteria for different countries. The company explained that it removes pharmaceutical websites from search results when national pharmaceutical regulators deem them unlawful and notify Google accordingly. Additionally, Google mentioned that it notifies users when search results have been removed and reports these removals to Lumen Database for transparency.
Lumen Database is a collaborative archive that compiles cease-and-desist notices and other legal documents related to online content. The inclusion of these removals helps provide transparency regarding Google’s actions in response to regulatory requests.
The MHRA also issued a statement emphasizing the risks associated with purchasing medicinal products from illegal online suppliers. Buying from unauthorized sources increases the likelihood of receiving falsified or unlicensed products that may not meet safety and quality standards set by the MHRA. The agency stated that it reviews instances of non-compliant activity related to online medicine sales on a case-by-case basis and takes appropriate enforcement actions to address such behavior.
Overall, the delisting of pharmaceutical websites selling hormones raises important questions about access to healthcare for marginalized communities, particularly transgender individuals. While regulatory bodies like the MHRA are tasked with ensuring public health and safety, concerns remain about the impact of such actions on individuals who rely on these websites for essential healthcare needs. As discussions continue about the balance between regulatory oversight and healthcare access, it is clear that this issue remains complex and multifaceted.
In conclusion, the delisting of these pharmaceutical websites serves as a reminder of the ongoing challenges faced by marginalized communities in accessing essential healthcare services. As debates around regulation, transparency, and inclusivity in healthcare continue, it is crucial to consider the impact of such decisions on those who rely on these services for their well-being.
Follow us on: Facebook for more LGBTQ+ news and updates at TrueQueer.
private trans hormones
